AIM ImmunoTech (AIM) Receivables (2017 - 2025)

AIM ImmunoTech's (AIM) quarterly Receivables came in at $7000.0 in Q4 2025, down 99.41% on a QoQ basis from $1.2 million in Q4 2023.

AIM ImmunoTech (AIM) Receivables (2017 - 2025) Analysis & Trends

AIM ImmunoTech (AIM) has 8 years of Receivables data on file, last reported at $7000.0 in Q4 2025.

Quarterly Receivables changed N/A year-over-year to $7000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7000.0 (changed N/A YoY) and the FY2025 annual result came in at $14000.0, changed N/A from the prior year.
Receivables fell to $7000.0 in Q4 2025, from $1.2 million in the prior quarter.
In the past five years, Receivables ranged from a high of $3.4 million in Q4 2022 to a low of $7000.0 in Q4 2025.
A 4-year average of $1.0 million and a median of $1.1 million in 2021 frame the typical range for Receivables.
Annual changes were most pronounced in 2021 — Receivables jumped 40.0% — and 2023, when it slumped 64.68%.
Tracing AIM's Receivables over 4 years: stood at $28000.0 in 2021, then soared by 11871.43% to $3.4 million in 2022, then tumbled by 64.68% to $1.2 million in 2023, then sank by 99.41% to $7000.0 in 2025.
The last three Receivables figures came in at $7000.0 (Q4 2025), $1.2 million (Q4 2023), and $1.7 million (Q3 2023), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	2.13 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	6.57 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	1.93 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	160.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	1.06 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	912.74 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	215.33 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	1.09 Bn
10	AIM ImmunoTech	4.34 Mn	-5.62 Mn	21,000.00	-

Download Data